IL227886A0 - Water-soluble protein membranes, methods for their preparation and their uses - Google Patents
Water-soluble protein membranes, methods for their preparation and their usesInfo
- Publication number
- IL227886A0 IL227886A0 IL227886A IL22788613A IL227886A0 IL 227886 A0 IL227886 A0 IL 227886A0 IL 227886 A IL227886 A IL 227886A IL 22788613 A IL22788613 A IL 22788613A IL 227886 A0 IL227886 A0 IL 227886A0
- Authority
- IL
- Israel
- Prior art keywords
- prepartion
- methods
- water soluble
- membrane proteins
- soluble membrane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161445740P | 2011-02-23 | 2011-02-23 | |
| PCT/US2012/026353 WO2012116203A1 (en) | 2011-02-23 | 2012-02-23 | Water soluble membrane proteins and methods for the preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL227886A0 true IL227886A0 (en) | 2013-09-30 |
Family
ID=46721234
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL227886A IL227886A0 (en) | 2011-02-23 | 2013-08-08 | Water-soluble protein membranes, methods for their preparation and their uses |
| IL261151A IL261151A (en) | 2011-02-23 | 2018-08-14 | Water-soluble membrane proteins, methods for their preparation and use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL261151A IL261151A (en) | 2011-02-23 | 2018-08-14 | Water-soluble membrane proteins, methods for their preparation and use |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US8637452B2 (enExample) |
| EP (1) | EP2709647B1 (enExample) |
| JP (1) | JP6263773B2 (enExample) |
| KR (1) | KR101963914B1 (enExample) |
| CN (2) | CN108752461A (enExample) |
| AU (3) | AU2012220558A1 (enExample) |
| BR (1) | BR112013020969A2 (enExample) |
| CA (1) | CA2827187C (enExample) |
| CL (1) | CL2013002419A1 (enExample) |
| EA (1) | EA201391041A1 (enExample) |
| IL (2) | IL227886A0 (enExample) |
| MX (1) | MX347038B (enExample) |
| SG (2) | SG192646A1 (enExample) |
| WO (1) | WO2012116203A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6263773B2 (ja) | 2011-02-23 | 2018-01-24 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質およびその調製および使用方法 |
| US9700521B2 (en) | 2013-03-14 | 2017-07-11 | Massachusetts Institute Of Technology | Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies |
| WO2014176524A2 (en) | 2013-04-25 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor |
| US9670264B2 (en) * | 2013-04-25 | 2017-06-06 | The Trustees Of The University Of Pennsylvania | Water soluble G-protein coupled receptor |
| WO2015149085A2 (en) | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
| JP2017520862A (ja) * | 2014-03-27 | 2017-07-27 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質ならびにその調製および使用方法 |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| GB2527286A (en) * | 2014-06-11 | 2015-12-23 | Rsr Ltd | Glycoprotein hormone receptor mutations |
| WO2016025781A1 (en) | 2014-08-15 | 2016-02-18 | Cornell University | Compositions and methods for making water-soluble integral membrane proteins |
| CN104198689A (zh) * | 2014-08-25 | 2014-12-10 | 李洁 | 一种检测g-蛋白耦联受体对缩血管物质反应的方法 |
| JP7061461B2 (ja) * | 2015-02-18 | 2022-04-28 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜貫通タンパク質ならびにその調製および使用方法 |
| CN104946674B (zh) * | 2015-06-17 | 2018-05-01 | 山东大学 | 一种腺苷三磷酸/双磷酸酶及其编码基因与应用 |
| CN106749602A (zh) * | 2016-12-30 | 2017-05-31 | 武汉金开瑞生物工程有限公司 | 一种助表达序列及其在无细胞表达adcy2蛋白中的应用 |
| US11293923B2 (en) * | 2017-09-01 | 2022-04-05 | Massachusetts Institute Of Technology | S-layer protein 2D lattice coupled detergent-free GPCR bioelectronic interfaces, devices, and methods for the use thereof |
| CN111448320B (zh) * | 2017-12-11 | 2024-03-15 | 安斯泰来制药株式会社 | 细胞膜穿透肽 |
| CN108245686B (zh) * | 2018-01-15 | 2019-08-13 | 中国科学院昆明动物研究所 | 人grk5基因的用途 |
| WO2021195177A1 (en) * | 2020-03-25 | 2021-09-30 | Massachusetts Institute Of Technology | Qty fc fusion water soluble receptor proteins |
| WO2021202186A2 (en) | 2020-03-31 | 2021-10-07 | Massachusetts Institute Of Technology | Qty fc fusion receptor proteins |
| US12377711B2 (en) | 2020-08-20 | 2025-08-05 | Denso International America, Inc. | Vehicle feature control systems and methods based on smoking |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US12251991B2 (en) | 2020-08-20 | 2025-03-18 | Denso International America, Inc. | Humidity control for olfaction sensors |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US12269315B2 (en) | 2020-08-20 | 2025-04-08 | Denso International America, Inc. | Systems and methods for measuring and managing odor brought into rental vehicles |
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US544021A (en) * | 1895-08-06 | William k | ||
| NZ240718A (en) | 1990-11-30 | 1996-10-28 | Bio Technology General Corp | Somatotropin analogues carrying mutations in the alpha-helix-1 region |
| US5739273A (en) * | 1992-02-12 | 1998-04-14 | Yale University | Transmembrane polypeptide and methods of use |
| JPH09278793A (ja) * | 1996-04-10 | 1997-10-28 | Kinichiro Miura | ポリペプチド |
| US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| WO2000053624A1 (en) * | 1999-03-11 | 2000-09-14 | Gryphon Sciences | Chemical synthesis and use of soluble membrane protein receptor domains |
| US20020160416A1 (en) | 2000-02-11 | 2002-10-31 | Boyle William J. | Receptor from TNF family |
| US20030143668A1 (en) * | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
| EP1593060A2 (en) | 2003-01-21 | 2005-11-09 | The Trustees Of The University Of Pennsylvania | Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa |
| DE102004033902A1 (de) * | 2004-07-14 | 2006-02-16 | Zentaris Gmbh | Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's) |
| EP1789452B1 (en) | 2004-08-25 | 2012-04-25 | Janssen Pharmaceutica NV | Relaxin-chimeric polypeptides and their preparation and use |
| WO2006086402A2 (en) * | 2005-02-08 | 2006-08-17 | Research Development Foundation | Compositions and methods related to soluble g-protein coupled receptors(sgpcrs) |
| BRPI0502759B1 (pt) * | 2005-06-30 | 2014-02-25 | óleo lubrificante e composição lubrificante para uma máquina de refrigeração | |
| WO2007089899A2 (en) * | 2006-02-01 | 2007-08-09 | Oklahoma Medical Research Foundation | Water-soluble (g protein)-coupled receptor protein |
| WO2007141309A2 (en) | 2006-06-09 | 2007-12-13 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
| EP2121919B1 (en) | 2007-03-22 | 2012-02-08 | Heptares Therapeutics Limited | Mutant g-protein coupled receptors and methods for selecting them |
| WO2008143910A2 (en) * | 2007-05-18 | 2008-11-27 | University Of Massachusetts | A strategy for cloning and expressing the extracellular domains of receptors as soluble proteins |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| WO2008068534A2 (en) | 2008-03-05 | 2008-06-12 | Heptares Therapeutics Limited | Crystal structure of a betal -adremergi c receptor and uses thereof |
| GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| BR112012019540B1 (pt) | 2010-02-05 | 2021-09-28 | Heptares Therapeutics Limited | Composto, uso de um composto, formulação farmacêutica, e, processo para a preparação de um composto |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| WO2012098413A1 (en) | 2011-01-21 | 2012-07-26 | Heptares Therapeutics Limited | Mutant g-protein coupled receptor proteins and methods for producing them |
| JP6263773B2 (ja) | 2011-02-23 | 2018-01-24 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質およびその調製および使用方法 |
| WO2012120315A2 (en) | 2011-03-10 | 2012-09-13 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
| US20130273585A1 (en) | 2012-04-11 | 2013-10-17 | Gangagen, Inc. | Soluble cytoplasmic expression of heterologous proteins in escherichia coli |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| WO2015149085A2 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
| JP2017520862A (ja) | 2014-03-27 | 2017-07-27 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質ならびにその調製および使用方法 |
-
2012
- 2012-02-23 JP JP2013555565A patent/JP6263773B2/ja active Active
- 2012-02-23 CN CN201810684571.XA patent/CN108752461A/zh active Pending
- 2012-02-23 CA CA2827187A patent/CA2827187C/en not_active Expired - Fee Related
- 2012-02-23 WO PCT/US2012/026353 patent/WO2012116203A1/en not_active Ceased
- 2012-02-23 MX MX2013009715A patent/MX347038B/es active IP Right Grant
- 2012-02-23 EA EA201391041A patent/EA201391041A1/ru unknown
- 2012-02-23 US US13/403,725 patent/US8637452B2/en active Active
- 2012-02-23 CN CN2012800096906A patent/CN103458915A/zh active Pending
- 2012-02-23 SG SG2013059811A patent/SG192646A1/en unknown
- 2012-02-23 AU AU2012220558A patent/AU2012220558A1/en not_active Abandoned
- 2012-02-23 BR BR112013020969A patent/BR112013020969A2/pt not_active Application Discontinuation
- 2012-02-23 SG SG10201701547VA patent/SG10201701547VA/en unknown
- 2012-02-23 KR KR1020137024789A patent/KR101963914B1/ko active Active
- 2012-02-23 EP EP12750085.8A patent/EP2709647B1/en active Active
-
2013
- 2013-08-08 IL IL227886A patent/IL227886A0/en active IP Right Grant
- 2013-08-21 CL CL2013002419A patent/CL2013002419A1/es unknown
- 2013-12-13 US US14/105,252 patent/US9309302B2/en active Active
-
2016
- 2016-03-23 US US15/078,036 patent/US10035837B2/en active Active
- 2016-03-29 AU AU2016201914A patent/AU2016201914A1/en not_active Abandoned
-
2017
- 2017-11-15 AU AU2017261525A patent/AU2017261525A1/en not_active Abandoned
-
2018
- 2018-07-13 US US16/034,549 patent/US20180312562A1/en not_active Abandoned
- 2018-08-14 IL IL261151A patent/IL261151A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013020969A2 (pt) | 2018-07-10 |
| SG192646A1 (en) | 2013-09-30 |
| US10035837B2 (en) | 2018-07-31 |
| US20180312562A1 (en) | 2018-11-01 |
| EP2709647B1 (en) | 2019-08-07 |
| CN103458915A (zh) | 2013-12-18 |
| CA2827187A1 (en) | 2012-08-30 |
| JP6263773B2 (ja) | 2018-01-24 |
| US20160264640A1 (en) | 2016-09-15 |
| MX347038B (es) | 2017-04-10 |
| JP2014508763A (ja) | 2014-04-10 |
| AU2012220558A1 (en) | 2013-08-22 |
| CA2827187C (en) | 2019-01-08 |
| US9309302B2 (en) | 2016-04-12 |
| EA201391041A1 (ru) | 2014-04-30 |
| EP2709647A4 (en) | 2015-01-21 |
| AU2016201914A1 (en) | 2016-04-21 |
| US8637452B2 (en) | 2014-01-28 |
| US20120252719A1 (en) | 2012-10-04 |
| CL2013002419A1 (es) | 2014-06-06 |
| EP2709647A1 (en) | 2014-03-26 |
| US20140243277A1 (en) | 2014-08-28 |
| CN108752461A (zh) | 2018-11-06 |
| WO2012116203A1 (en) | 2012-08-30 |
| IL261151A (en) | 2018-10-31 |
| KR101963914B1 (ko) | 2019-03-29 |
| KR20140027117A (ko) | 2014-03-06 |
| AU2017261525A1 (en) | 2017-12-07 |
| SG10201701547VA (en) | 2017-03-30 |
| MX2013009715A (es) | 2014-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261151A (en) | Water-soluble membrane proteins, methods for their preparation and use | |
| IL288203B (en) | Meditops and Meditop binding antibodies and their use | |
| IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
| IL259436A (en) | Antibodies against 3angptl and their uses | |
| ZA201400562B (en) | Axmi205 variant proteins and methods for their use | |
| IL232399A0 (en) | Anti-2fgfr antibodies and their use | |
| IL230918A0 (en) | Modified proteins and peptides | |
| SG184289A1 (en) | Novel peptides and methods for their preparation and use | |
| GB201115529D0 (en) | Antibodies, uses and methods | |
| GB201115280D0 (en) | Antibodies, uses and methods | |
| EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
| HRP20181457T1 (hr) | Anti-htra1 protutijela i postupci uporabe | |
| SG10201604332XA (en) | Membrane and method for making the same | |
| SG2014010334A (en) | Fn14 binding proteins and uses thereof | |
| PL2744831T3 (pl) | Białko fuzyjne transferryna-tumstatyna oraz sposoby jego wytwarzania i stosowania | |
| EP2771689A4 (en) | PEPTIDES USP2A AND ANTIBODIES | |
| IL231507A0 (en) | Antibodies directed against marker peptides, methods and uses | |
| AU2011902431A0 (en) | Fusion Proteins and Use Thereof | |
| GB201121236D0 (en) | Proteins and peptides | |
| GB201121233D0 (en) | Modified proteins and peptides | |
| GB201121226D0 (en) | Modified proteins and peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |